PT-141Melanocortin Peptide
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| Alpha Peptides 8/10 COA ✓Ships: USCredit/debit card Verification & shipping8/10 COA ✓Ships: USCredit/debit card | $22.07 | $22.07Checked jul 31, 2026 | Jul 31, 2026 | Buy PT-141 from Alpha Peptides |
| NextGen Peptides 8/10 COA ✓Ships: USVisa · American Express Verification & shipping8/10 COA ✓Ships: USVisa · American Express | $22.49 | $22.49Checked jul 24, 2026 | Jul 24, 2026 | Buy PT-141 from NextGen Peptides |
| Amino Club 10/10 COA ✓Ships: US + internationalVisa · Mastercard Verification & shipping10/10 COA ✓Ships: US + internationalVisa · Mastercard | $23.99 | $23.99Checked today | Today | Buy PT-141 from Amino Club |
| Promino 5/10 COA ✓Ships: USCredit/debit card Verification & shipping5/10 COA ✓Ships: USCredit/debit card | $24.29 | $24.29Checked jul 17, 2026 | Jul 17, 2026 | Buy PT-141 from Promino |
| Purus Peptides 8.5/10 COA ✓Ships: USCredit/debit card Verification & shipping8.5/10 COA ✓Ships: USCredit/debit card | $24.80 | $24.80Checked yesterday | Yesterday | Buy PT-141 from Purus Peptides |
| Ascension Peptides 8.5/10 COA ✓Ships: USVisa · Mastercard Verification & shipping8.5/10 COA ✓Ships: USVisa · Mastercard | $25.00 | $25.00Checked apr 16, 2026 | Apr 16, 2026 | Buy PT-141 from Ascension Peptides |
Research details
PT-141 — research data
Overview
About PT-141
Mechanism of action
Melanocortin receptor agonist (MC3R, MC4R). Acts centrally in the hypothalamus to stimulate sexual arousal independent of the vascular system. Does not affect blood pressure like PDE5 inhibitors.
Safety profile
Nausea (most common), flushing, headache, transient blood pressure increase, spontaneous erections, hyperpigmentation with repeated use. · FDA-approved for HSDD; nausea common (40%); transient BP increase; limited to 1 dose/24hr
Storage
Stability & handling
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Uncontrolled hypertension.
Known cardiovascular disease.
Transient BP increase (~6 mmHg SBP, ~3 mmHg DBP) lasting ~8 hours after each dose. Avoid in patients with CV risk factors.
Related pages
More on PT-141
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first centrally-acting pharmacological treatment for female sexual dysfunction.
- Two identical Phase 3 RCTs confirmed statistically and clinically significant increases in satisfying sexual events and decreases in distress scores vs placebo.